GREIFSWALD, Germany--(BUSINESS WIRE)--Braun Beteiligungs GmbH (BBG) has acquired a stake in Enzymicals AG. The participation agreement was signed on 8th ofJune 2012. This growth financing will further expand the collaboration of Enzymicals AG, Herbrand PharmaChemicals GmbH and BRAIN AG. BRAIN AG has also invested an additional sum, thereby underscoring the significance of the alliance.
Commenting on his company’s important step toward the future, Ulf Menyes, CEO of Enzymicals AG, noted: “We at Enzymicals AG are delighted that we have made further progress in expanding our intense customer relationships on the chemicals/pharmaceuticals market by the investment from BBG.
The positive effects that will result from closer collaboration with Herbrand PharmaChemicals GmbH in market-orientated biocatalytic process development and with BRAIN AG in enzyme identification will be very beneficial to all parties involved. We are now presenting ourselves as a strong alliance on the market. In order to meet the resulting higher standards, expanding the growth financing by increasing the capital is a logical step for our company.”
The BBG alliance includes Herbrand PharmaChemicals GmbH, Riemser Arzneimittel GmbH, CheplapharmArzneimittel GmbH and WALTER RITTER GmbH &Co. KG.
Norbert Braun, commercial manager of BBG, commented: “BBG’s stake in Enzymicals AG is a reasonable addition to our portfolio in the pharmaceutical industry. We will use the synergies created by our investments in this area to present our companies with a forward-looking focus on the market. We will concentrate on pioneering and innovative technologies such as biocatalysis. This is firmly established in the market environment of industrial biotechnology, generates high growth rates and is thus a logical further step for our strategy in this segment.”
The growth financing will help the collaboration of Enzymicals, BRAIN and Herbrand PharmaChemicals progress further.
The core competencies of each company complement each other very well. BRAIN AG identifies, optimises and produces new enzymes. Enzymicals AG handles application and process development of biocatalytic processes for chemical and pharmaceutical products and process-orientated enzyme optimisation. As the final step, there is Herbrand PharmaChemicals GmbH’s biocatalytic production of active pharmaceutical ingredients (APIs) in compliance with cGMP. This company alliance represents anunique value chain, from new enzymes to chemical/pharmaceutical products produced with biocatalysts (including the option to manufacture the complete drug within the network).
Jürgen Eck, CTO of BRAIN AG, noted: “The collaboration with BBG is a major step for all parties towards reinforcing our international competitive edge in the field of industrial biocatalysis for chemical/pharmaceutical applications. We feel that the partnership will open up completely new opportunities to give the products and processes from industrial biocatalysis the attention they deserve. Our collaboration will provide us with direct access to the international markets.”